IIROC Trade Resumption – AVCN

Canada NewsWire

TORONTO, Nov. 13, 2020 /CNW/ – Trading resumes in:

Company: Avicanna Inc.

TSX Symbol: AVCN

All Issues: Yes

Resumption (ET): ‎12‎:‎30‎ PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

GreenVision Acquisition Corp. Announces Contribution to Trust Account to Extend Period to Complete Business Combination

GreenVision Acquisition Corp. Announces Contribution to Trust Account to Extend Period to Complete Business Combination

NEW YORK–(BUSINESS WIRE)–
GreenVision Acquisition Corp. (Nasdaq:GRNV), a special purpose acquisition company (“GreenVision”), announced today that it has deposited the amount of $575,000 into its trust account (the “Trust Account”) in order to extend the period of time that it has to complete a business combination for an additional period of three (3) months, from November 21, 2020 to February 21, 2021. The funds deposited into the Trust Account were previously provided by Accountable Healthcare America, Inc. (“AHA”) under the terms of the definitive Merger Agreement entered into by the parties on August 26, 2020. GreenVision issued an unsecured promissory note in an amount of $575,000 to AHA in accordance with its governing documents. The purpose of the extension is to extend the time for GreenVision and AHA to complete the previously announced business combination.

About GreenVision Acquisition Corp.

GreenVision Acquisition Corp. is a newly organized blank check company formed under the laws of the State of Delaware for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, but it intends to focus on target businesses operating in North America, Europe and Asia (excluding China) in the life sciences and healthcare industries.

About Accountable Healthcare America, Inc.

AHA is a technology-enabled population health management company. For more information, please visit www.ahahealthcare.net. Information on our website does not comprise a part of this press release.

Safe Harbor Language

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this press release regarding the proposed business combination, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed business combination, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the proposed transactions contemplated by the definitive agreement. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on GreenVision and AHA’s managements’ current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement or could otherwise cause the Business Combination to fail to close; (2) the outcome of any legal proceedings that may be instituted against GreenVision or AHA following the announcement of the Merger Agreement and the Business Combination; (3) the inability to complete the Business Combination, including due to failure to obtain approval of the stockholders of GreenVision or other conditions to closing in the Merger Agreement; (4) the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the Business Combination; (5) the inability to obtain the listing of the shares of common stock of the post-acquisition company on the Nasdaq Stock Market or any alternative national securities exchange following the Business Combination; (6) the risk that the announcement and consummation of the Business Combination disrupts current plans and operations; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (8) costs related to the Business Combination; (9) changes in applicable laws or regulations; (10) the possibility that AHA may be adversely affected by other economic, business, and/or competitive factors; (11) the impact of COVID-19 on the combined company’s business; and (12) other risks and uncertainties indicated from time to time in the proxy statement to be filed relating to the Business Combination, including those under “Risk Factors” therein, and in GreenVision’s other filings with the SEC. Some of these risks and uncertainties may in the future be amplified by the COVID-19 outbreak and there may be additional risks that GreenVision considers immaterial or which are unknown. A further list and description of risks and uncertainties can be found in GreenVision’s Annual Report on Form 10-K for the year ended December 31, 2019 and in the proxy statement on Schedule 14A that will be filed with the SEC by GreenVision in connection with the proposed transaction, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to GreenVision and AHA and speaks only as of the date on which it is made. GreenVision and AHA undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Additional Information and Where to Find It

GreenVision, AHA, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of GreenVision common stock in respect of the proposed transaction described herein. Information about GreenVision’s directors and executive officers and their ownership of GreenVision’s common stock is set forth in GreenVision’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC. Other information regarding the interests of the participants in the proxy solicitation will be included in the proxy statement pertaining to the proposed transaction when it becomes available. These documents can be obtained free of charge from the sources indicated below.

GreenVision has filed a preliminary proxy statement with the SEC and intends to file with the SEC an amended preliminary proxy statement and a definitive proxy statements in connection with the proposed business combination and other matters and will mail a definitive proxy statement to its stockholders as of the record date established for voting on the proposed business combination. GreenVision’s stockholders and other interested persons are advised to read, once available, the preliminary proxy statement and any amendments thereto and, once available, the definitive proxy statement, in connection with GreenVision’s solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the proposed business combination, because these documents will contain important information about GreenVision, AHA and the proposed business combination. GreenVision’s stockholders may also obtain a copy of the preliminary or definitive proxy statement, once available, as well as other documents filed with the SEC by GreenVision, without charge, at the SEC’s website located at www.sec.gov or by directing a request to: GreenVision Acquisition Corp., One Penn Plaza, 36th Floor, New York, New York 10019. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Non-Solicitation

This press release does not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This press release also does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

GreenVision:

David Fu, Chief Executive Officer
[email protected]

AHA:

Warren Hosseinion, Chief Executive Officer

818 618-1458

[email protected]

FOR ADDITIONAL INFORMATION:

The Equity Group Inc.

Devin Sullivan, Senior Vice President

[email protected]

Kalle Ahl, Vice President

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Health Technology Practice Management Finance Software

MEDIA:

Logo
Logo

Accumen Launches Market Insider Newsletter for Healthcare Leaders and Health Systems Nationally

Accumen will provide current healthcare news and thought leadership through its new digital publication

Phoenix, AZ, Nov. 13, 2020 (GLOBE NEWSWIRE) — Accumen Inc. is helping healthcare get better, faster. Today, Accumen announced the release of its second digital publication, Market Insider, for healthcare leaders nationally. Market Insider is available here.

Market Insider is a weekly compilation of pertinent, trending healthcare news, replete with insights from Accumen, focusing on improving laboratory and imaging department performance for hospitals and health systems. Market Insider also features a summary of current COVID cases and other related national metrics.

“I’m excited to expand our contributions to healthcare thought leadership through the release of Market Insider. It has been a valuable internal resource for more than a year, keeping our teams informed of news updates that directly impact our clients. Offering this resource to the broader market is a natural next step in achieving our mission of improving healthcare performance,” said BG Porter, chief executive officer of Accumen Inc. 

Accumen has been a healthcare thought leader for nearly 10 years, partnering with health systems to improve lab and imaging operations nationally and providing clinical expertise to help reduce costs and improve patient outcomes.

Through the launch of Market Insider, Accumen will expand its contribution to continuing education and performance improvement for hospitals, health systems and commercial laboratories. Accumen’s educational resources include Healthcare Performance Insider publicationand the Healthcare Performance Insider Podcastwhich feature best practices and leadership insights from healthcare leaders driving change today.

For institutions that need immediate access to COVID-19-related resources, Accumen provides laboratory, supply chain, imaging, and blood management rapid response tools, access to personal protective equipment, and other strategic resources through its COVID-19 Resource Center.

 

About Accumen Inc.

At Accumen, our focus is helping healthcare get better, faster. Accumen is a technology enabled organization that partners with hospital, health system, commercial laboratory, and payer clients, to provide strategic solutions and services that deliver sustainable performance improvements. Our offerings include lab and imaging transformation, consulting, supply chain optimization, lab outreach, 3D post-processing, patient blood management, test utilization, anemia management, and clinical data exchange. Accumen’s offerings enable our clients to achieve and exceed their cost, quality, and service targets, as well as deliver excellent patient care through evidence-based data and clinical decision support capabilities. Find out more at Accumen.com.

Disclaimer: Accumen has no authority, responsibility, or liability with respect to any clinical decisions made by – or in connection with – a provider’s laboratory, patient blood management, or other operations. Nothing herein and no aspect of any services provided by Accumen is intended – or shall be deemed – to subordinate, usurp, or otherwise diminish any providers’ sole authority and discretion with respect to all clinical decision-making for its patients.

 



Kimberly MacDowell
Accumen Inc
858 621 3167
[email protected]

Lisa Osborne
Rana Healthcare Solutions
206.992.5245
[email protected]

Quanterix to Participate in the Canaccord Medical Technologies and Diagnostics Forum

Quanterix to Participate in the Canaccord Medical Technologies and Diagnostics Forum

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President, Kevin Hrusovsky will participate in a virtual fireside chat discussion at the Canaccord Medical Technologies and Diagnostics Forum on November 19 at 10:30 a.m., EST. Hrusovsky will also host virtual one-on-one and group meetings with institutional investors that day.

A live webcast of the conversation will be available on the investor section of the Quanterix website at https://ir.quanterix.com/investor-relations. Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Media Contact:

PAN Communications

Staci Didner, (407) 734-7325

[email protected]

Investor Relations Contact:

Stephen Hrusovsky

(774) 278-0496

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Oncology Health Medical Devices Hospitals Research Science Biotechnology

MEDIA:

Logo
Logo

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of IPHI, EIDX, CEIX, and PNM Mergers

WILMINGTON, Del., Nov. 13, 2020 (GLOBE NEWSWIRE) —

Rigrodsky & Long, P.A. announces that it is investigating:

Inphi
Corporation
(N
ASDAQ GS:

IPHI

) regarding possible breaches of fiduciary duties and other violations of law related to Inphi’s agreement to be acquired by Marvell Technology Group Ltd. Under the terms of the agreement Inphi’s shareholders will receive 2.323 shares of Marvell Technology’s common stock and $66.00 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-inphi-corporation.

Eidos Therapeutics, Inc. (NASDAQ GS:

EIDX

) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio Pharma, Inc. Under the terms of the agreement, Eidos’ shareholders will receive 1.85 shares of BridgeBio common stock or $73.26 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-eidos-therapeutics-inc.

CONSOL Energy
Inc.
(
N
YSE:

CEIX

) regarding possible breaches of fiduciary duties and other violations of law related to CONSOL Energy’s agreement acquire all of the publicly held common units of CONSOL Coal Resources LP in an all-stock transaction valued at approximately $34.4 million.   To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-consol-energy-inc.

PNM Resources, Inc. (NYSE:

PNM

) regarding possible breaches of fiduciary duties and other violations of law related to PNM’s agreement to be acquired by Avangrid, Inc. Under the terms of the agreement PNM’s shareholders will receive $50.30 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-pnm-resources-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:         

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com



Jordan Park Group Gains Approval for Perspecta Trust Acquisition from New Hampshire Banking Department

San Francisco, Nov. 13, 2020 (GLOBE NEWSWIRE) — Jordan Park Group, an independent financial advisory firm, today announced it has received regulatory approval from the New Hampshire Banking Department (NHBD) to acquire Perspecta Trust, which provides fiduciary, investment management, and wealth transfer planning services.   

The acquisition brings together two firms that serve a similar client base of ultra-high-net-worth individuals and families and will enable the new entity to offer a more robust suite of services to their respective client bases.  

Jordan Park Group was founded in 2017 by Frank Ghali, following his tenure of nearly two decades at Goldman Sachs. Perspecta Trust was formed in 2007 by investors Paul Montrone and Paul Meister. Upon closing, Perspecta will change its name to Jordan Park Trust Company; however, there will be no change to its operations and Mr. Meister will continue to serve on its board of directors. It will also continue to operate as a New Hampshire state-chartered trust company.

About Jordan Park Group
Jordan Park is an independent financial advisory firm with offices in San Francisco and New York. Jordan Park provides investment management and financial advice to a distinct community of individuals, families, and institutions.

About Perspecta Trust
Perspecta Trust is a New Hampshire-based non-depository trust company that provides fiduciary, investment management, and wealth transfer planning services to ultra-high net worth families. Perspecta Trust also works with families to develop and administer family trust companies. 



Heather Brownlie, Jordan Park
415-417-3000
[email protected]
[email protected]  

FLEETCOR to Present at Citi’s 2020 Financial Technology Virtual Conference

FLEETCOR to Present at Citi’s 2020 Financial Technology Virtual Conference

ATLANTA–(BUSINESS WIRE)–
FLEETCOR Technologies, Inc. (NYSE: FLT) today announced that the Company will host a fireside chat at Citi’s 2020 Financial Technology Virtual Conference on Monday, November 16, 2020. The discussion will begin at 9:45 AM ET.

Investors and interested parties can access this fireside chat by visiting the Company’s investor relations website at http://investor.fleetcor.com/.

About FLEETCOR

FLEETCOR Technologies (NYSE: FLT) is a leading global business payments company that simplifies the way businesses manage and pay their expenses. The FLEETCOR portfolio of brands help companies automate, secure, digitize and control payments on behalf of, their employees and suppliers. FLEETCOR serves businesses, partners and merchants in North America, Latin America, Europe, and Asia Pacific. For more information, please visit www.FLEETCOR.com.

Investor Relations

Jim Eglseder, 770-417-4697

[email protected]

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Professional Services Data Management Security Technology Finance Banking

MEDIA:

Logo
Logo

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of NAV, PE, CXO, and CBLI Mergers

WILMINGTON, Del., Nov. 13, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating:

Navistar International
Corporation
(N
YSE
:

NAV


)
regarding possible breaches of fiduciary duties and other violations of law related to Navistar’s agreement to be acquired by TRATON SE. Under the terms of the agreement, Navistar’s shareholders will receive $44.50 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-navistar-international-corporation.

Parsley Energy
, Inc. (N
YSE:

PE

) regarding possible breaches of fiduciary duties and other violations of law related to Parsley Energy’s agreement to be acquired by Pioneer Natural Resources Company. Under the terms of the agreement, Parsley Energy’s shareholders will receive 0.1252 shares of Pioneer Natural Resources per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-parsley-energy-inc.

Concho Resources Inc. (NYSE:

CXO

) regarding possible breaches of fiduciary duties and other violations of law related to Concho Resources’ agreement to be acquired by ConocoPhillips. Under the terms of the agreement Concho Resources’ shareholders will receive 1.46 shares of ConocoPhillips’ common stock per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-concho-resources-inc.

Cleveland
BioLabs
, Inc. (NASDAQ
CM:

CBLI

) regarding possible breaches of fiduciary duties and other violations of law related to Cleveland BioLabs’ agreement to merge with Cytocom, Inc. Under the terms of the agreement, Cleveland BioLabs will issue a number of shares of Cleveland BioLabs’ common stock to shareholders of Cytocom. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-cleveland-biolabs-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:         

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com

 



Fannie Mae Prices $783 Million Multifamily DUS REMIC (FNA 2020-M52) Under Its GeMS Program

PR Newswire

WASHINGTON, Nov. 13, 2020 /PRNewswire/ — Fannie Mae (OTCQB: FNMA) priced a $783 million Multifamily DUS® REMIC under its Fannie Mae Guaranteed Multifamily Structures (Fannie Mae GeMS™) program on November 10, 2020. FNA 2020-M52 marks the tenth Fannie Mae GeMS issuance of 2020.

“In a week marked by market uncertainty, rate volatility, and climbing COVID-19 numbers, we were pleased with the execution of the M52,” said Dan Dresser, Senior Vice President, Multifamily Capital Markets & Pricing. “This deal brought our total GeMS issuance for 2020 to $8.5 billion, which represents only a fraction of the entire FNA market this year as ACES issuance hit record levels. With one more month of issuance to go, the combined GeMS and ACES volumes have reached $26.3 billion over 50 deals. The program allows investors and broker dealers to structure REMICs with their own DUS collateral – a flexibility that has been particularly helpful to liquidity given the year’s rate environment. As we head into December and prepare to close the books on 2020, we would like to express our appreciation for the support of our GeMS investor community and the broker dealer network.”

All classes of FNA 2020-M52 are guaranteed by Fannie Mae with respect to the full and timely payment of interest and principal. The structure details for the multi-tranche offering can be found in the table below:


Class


Original Face


Weighted Average Life


Coupon (%)


Coupon Type


Spread


Offered


Price


APT

$121,669,043

5.10

0.864

Fixed

Not Offered

Not Offered


X1

$121,669,043

4.98

2.472

WAC IO

Not Offered

Not Offered


A1

$85,100,000

5.77

0.878

Fixed

S+29

100


A2

$501,596,201

9.76

1.319

WAC

S+39

100.07


A3

$75,000,000

9.83

1.200

Fixed

S+35

99.11


X

$85,100,000

5.75

0.441

WAC IO

Not Offered

Not Offered


X3

$75,000,000

9.33

0.119

WAC IO

Not Offered

Not Offered


Total


$783,365,244

 



Group 1 Collateral


UPB:

$3,150,550,015


Collateral: 

4 REMIC Certificates (199 Fannie Mae DUS MBS)


Underlying REMIC Trust/Class 1:

FNA 2019-M1-A1


Original Principal of Contributed Portion of Class: 

$79,805,000


Geographic Distribution: 

CA (24.89%), GA (22.19%), FL (19.91%)


Underlying REMIC Trust/Class 2: 

FNA 2018-M4-A1


Original Principal of Contributed Portion of Class: 

$30,500,000


Geographic Distribution: 

FL (27.37%), TX (11.77%), LA (8.89%)


Underlying REMIC Trust/Class 3: 

FNA 2018-M14-A2


Original Principal of Contributed Portion of Class: 

$25,000,000


Geographic Distribution: 

CA (44.26%), FL (9.59%), MD (8.05%)


Underlying REMIC Trust/Class 4: 

FNA 2018-M10-A1


Original Principal of Contributed Portion of Class: 

$1,600,000


Geographic Distribution: 

CA (27.94%), TX (9.14%), NC (9.01%)


Weighted Average Debt Service Coverage Ratio (DSCR): 

1.88x


Weighted Average Loan-to-Value (LTV): 

64.5%



Group 2 Collateral


UPB: 

$661,696,201


Collateral: 

132 Fannie Mae DUS MBS


Geographic Distribution: 

CA (29.6%), GA (11.0%), FL (9.07%)


Weighted Average Debt Service Coverage Ratio (DSCR): 

2.48x


Weighted Average Loan-to-Value (LTV): 

59.6%

For additional information, please refer to the Fannie Mae GeMS REMIC Term Sheet (FNA 2020-M52) available on the Fannie Mae GeMS Archive page.

About Fannie Mae
Fannie Mae helps make the 30-year fixed-rate mortgage and affordable rental housing possible for millions of Americans. We partner with lenders to create housing opportunities for families across the country. We are driving positive changes in housing finance to make the home buying process easier, while reducing costs and risk. To learn more, visit:
fanniemae.com | Twitter | Facebook | LinkedIn | Instagram | YouTube | Blog

Fannie Mae Newsroom

https://www.fanniemae.com/news

Photo of Fannie Mae

https://www.fanniemae.com/resources/img/about-fm/fm-building.tif

Fannie Mae Resource Center
1-800-2FANNIE

Certain statements in this release may be considered forward-looking statements within the meaning of federal securities laws. In addition, not all securities will have the characteristics discussed in this release. Before investing in any Fannie Mae issued security, you should read the prospectus and prospectus supplement pursuant to which such security is offered. You should also read our most current Annual Report on Form 10-K and our reports on Form 10-Q and Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) available on the Investor Relations page of our Web site at www.fanniemae.com and on the SEC’s Web site at www.sec.gov.

Cision View original content:http://www.prnewswire.com/news-releases/fannie-mae-prices-783-million-multifamily-dus-remic-fna-2020-m52-under-its-gems-program-301172880.html

SOURCE Fannie Mae

Tuscan Holdings Corp. Announces Intent to Combine With Microvast Inc.

PR Newswire

NEW YORK, Nov. 13, 2020 /PRNewswire/ — Tuscan Holdings Corp. (Nasdaq: THCB) (“Tuscan”) today confirmed that it has signed a letter of intent (“LOI”) related to a business combination with Microvast Inc., a market leading provider of next-generation battery technologies for commercial and specialty use electric vehicles (“Microvast” or the “Company”). 

Founded by Yang Wu in 2006, Microvast is focused on driving mass adoption EVs and its battery technology boasts best-in-class charging speed, battery life, energy density and safety performance. The Company has been an innovative industry leader for over a decade and has clear visibility to future growth from its existing pipeline across commercial markets including e-buses, vans, trucks, passenger vehicles, automated guided vehicles, forklifts and mining trucks.  Microvast is a vertically integrated battery technology company with R&D and production capabilities that span cell chemistries, materials, cells, modules and packs.  In addition, Microvast has an industry leading manufacturing price point for batteries with ongoing further improvements in development.

Tuscan also announced that in connection with the intended transaction with Microvast, Ahmed Fattouh and Brian Pham of InterPrivate Capital are acting as Senior Advisors to Tuscan. Mr. Fattouh and Mr. Pham, who  have prior experience in automotive technology as SPAC sponsors, will continue to advise the Tuscan team through the business combination.

“Microvast has a compelling financial profile, with significant historical revenues as well as projected growth and profitability.  With its battery technology installed in over 28,000 vehicles worldwide, an impressive,  growing list of global OEM customers, and a strategic partnership with Fiat Power Train Industrial, Microvast is a proven technology leader driving the mass adoption of EVs.  We are excited to partner with Mr. Wu and his experienced team and believe the valuation negotiated provides long term intrinsic value to Tuscan shareholders.  We look forward to supporting Microvast in its next phase of growth as a public company,” said Stephen Vogel, Chairman and CEO of Tuscan.

Yang Wu, Microvast’s founder, Chairman and CEO added: “Our potential transition into a public company will help continue to fuel our design and development of market-leading ultra-fast charging, long-life battery power systems. Microvast expects to generate over $100 million of revenue this financial year. With the automotive technology experience and capital this transaction with Tuscan is intended to provide, we are confident we can build upon our established success and accelerate our growth in the electric vehicle battery industry.”

Completion of the transaction is subject to, among other things, the execution of a definitive agreement, approval by the two companies’ boards, satisfaction of customary closing conditions and approval of the transaction by each company’s shareholders. Accordingly, there can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms currently contemplated or at all.

Additional Information and Where to Find It

Additional information regarding Microvast can be found on the Company’s website www.microvast.com 

If a legally binding definitive agreement is entered into, a full description of the terms of the transaction will be provided in a registration statement and/or a proxy statement of Tuscan (the “Transaction Proxy Statement”), to be filed with the U.S. Securities and Exchange Commission (the “SEC”). Tuscan urges investors, stockholders and other interested persons to read, when available, the preliminary Transaction Proxy Statement as well as other documents filed with the SEC because these documents will contain important information about Tuscan, Microvast and the transaction.

Investors and security holders of Tuscan are advised to read, when available, the preliminary Transaction Proxy Statement and definitive Transaction Proxy Statement, and any amendments thereto, because these documents will contain important information about proposed transaction. The definitive Transaction Proxy Statement will be mailed to Tuscan’s stockholders of record as of a record date to be established for the special meeting of stockholders relating to the proposed transaction. Stockholders will also be able to obtain copies of the Transaction Proxy Statement, without charge, once available, at the SEC’s website at www.sec.gov or by directing a request to:  Tuscan Holdings, Corp., 135 E. 57th St., 17th Floor, New York, NY 10022.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Tuscan’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include: the inability of Tuscan to enter into a definitive agreement with respect to the proposed business combination with Microvast or to complete the contemplated transaction; matters discovered by Tuscan or Microvast as they complete their respective due diligence investigation of the other; the impact of COVID-19 on Tuscan or Microvast; the risk that the approval of the stockholders of Tuscan for the potential transaction is not obtained; the inability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, the amount of funds available in Tuscan’s trust account following any redemptions by Tuscan stockholders; the ability to meet Nasdaq’s listing requirements following the consummation of the transaction; costs related to the proposed transaction; and those factors discussed in Tuscan’s prospectus relating to its initial public offering filed with the SEC. Tuscan does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Participants in the Solicitation

Tuscan and its directors and executive officers may be considered participants in the solicitation of proxies with respect to the potential transaction described herein under the rules of the SEC. Information about the directors and executive officers of Tuscan and a description of their interests in Tuscan will be set forth in the Transaction Proxy Statement when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Non-Solicitation

The disclosure herein is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Tuscan, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a definitive document.

Contacts

Tuscan Holdings Corp.:
Stephen Vogel
Chairman & CEO
Email: [email protected]

Media / Investors:
Ashish Gupta
Investor Relations
Telephone: 646-677-1875  
Email: [email protected]

 

 

Cision View original content:http://www.prnewswire.com/news-releases/tuscan-holdings-corp-announces-intent-to-combine-with-microvast-inc-301172882.html

SOURCE Tuscan Holdings Corp.